Want to see MNKD full AI Analyst Report?
MNKD Stock Chart & Stats
$4.09
-$0.08(-1.82%)
At close: 4:00 PM EDT
$4.09
-$0.08(-1.82%)
Day’s Range― - ―
52-Week Range$2.23 - $6.51
Previous CloseN/A
Volume958.79K
Average Volume (3M)3.93M
Market Cap
$1.31B
Enterprise Value$1.64K
Total Cash (Recent Filing)$111.13M
Total Debt (Recent Filing)$330.85M
Price to Earnings (P/E)―
Beta1.22
Next Earnings
Nov 10, 2026EPS Estimate
-0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.14
Shares Outstanding321,544,500
10 Day Avg. Volume2,459,535
30 Day Avg. Volume3,934,317
Financial Highlights & Ratios
PEG Ratio-3.54
Price to Book (P/B)-33.97
Price to Sales (P/S)4.97
P/FCF Ratio126.60
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$8.29Price Target Upside102.73% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-0.02
Revenue Forecast (FY)$443.47M
Bulls Say, Bears Say
Bulls Say
Strong Revenue GrowthMannKind’s multi-year revenue expansion indicates growing commercial traction and broader adoption of its products. Continued top-line growth can improve operating leverage, support investment in the inhalation platform, and strengthen the company’s ability to scale its commercial and partnering activities over the next several quarters.
High Gross MarginA gross margin near 79% provides substantial contribution from each dollar of revenue before operating expenses. This favorable product economics creates a foundation for future profitability if revenue continues scaling and management can control operating costs, making margin quality a durable business strength.
Multiple Platform Revenue ChannelsMannKind has several ways to monetize its Technosphere technology, including its own Afrezza product, collaboration revenue from TYVASO DPI, pipeline partnering, and contract manufacturing. This platform-based model creates multiple commercial pathways beyond a single marketed product.
Bears Say
Negative Equity And Elevated DebtNegative equity and meaningful debt leave MannKind with limited financial cushion if operating performance weakens. The stressed capital structure can constrain investment choices, increase dependence on financing, and make the company more vulnerable to higher funding costs or additional obligations.
Return To Cash BurnThe reversal from positive free cash flow in 2024 and 2025 to substantial TTM cash burn weakens internally generated funding capacity. Persistent cash consumption would increase the importance of liquidity management and could require MannKind to direct future capital toward operations rather than growth.
Unstable ProfitabilityDespite strong revenue growth and high gross margin, MannKind has not yet demonstrated durable earnings conversion. The return to a sizable TTM loss and very thin operating margin suggests operating expenses remain a material burden, limiting the predictability of future profits.
MannKind News
MNKD FAQ
What was Mannkind Corp.’s price range in the past 12 months?
Mannkind Corp. lowest stock price was $2.23 and its highest was $6.51 in the past 12 months.
What is Mannkind Corp.’s market cap?
Mannkind Corp.’s market cap is $1.31B.
When is Mannkind Corp.’s upcoming earnings report date?
Mannkind Corp.’s upcoming earnings report date is Nov 10, 2026 which is in 63 days.
How were Mannkind Corp.’s earnings last quarter?
Mannkind Corp. released its earnings results on Aug 05, 2026. The company reported -$0.06 earnings per share for the quarter, missing the consensus estimate of -$0.008 by -$0.052.
Is Mannkind Corp. overvalued?
According to Wall Street analysts Mannkind Corp.’s price is currently Undervalued.
Does Mannkind Corp. pay dividends?
Mannkind Corp. does not currently pay dividends.
What is Mannkind Corp.’s EPS estimate?
Mannkind Corp.’s EPS estimate is -0.06.
How many shares outstanding does Mannkind Corp. have?
Mannkind Corp. has 321,544,500 shares outstanding.
What happened to Mannkind Corp.’s price movement after its last earnings report?
Mannkind Corp. reported an EPS of -$0.06 in its last earnings report, missing expectations of -$0.008. Following the earnings report the stock price went down -5.122%.
Which hedge fund is a major shareholder of Mannkind Corp.?
Currently, no hedge funds are holding shares in MNKD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
MannKind Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$8.29 (102.73% Upside)
$8.29 (102.73% Upside)
Blogger Sentiment
Neutral
MNKD Sentiment 56%
Sector Average 60%
Sector Average 60%
Hedge Fund Trend
Decreased
By 867.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 7.2%
Last 30 Days ▼ 7.2%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-23.97%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
77.87%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Mannkind Corp.
MannKind Corporation operates as a biopharmaceutical firm, primarily focused on innovating and bringing to market respiratory-delivered treatments. Its efforts are directed towards tackling endocrine system disorders and rare lung conditions within the U.S. market. The company's key product is Afrezza, an inhaled insulin designed to improve glycemic control for adults managing diabetes. MannKind also actively markets Thyquidity, promoting it to adult and pediatric endocrinologists and other healthcare professionals for the treatment of hypothyroidism. In terms of collaborations, MannKind holds a strategic licensing and partnership agreement with United Therapeutics Corporation. Furthermore, it is collaborating with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), which is a synthetic variant of human vasoactive intestinal peptide intended to shield cells from inflammatory processes. Established in 1991, MannKind Corporation's corporate offices are located in Westlake Village, California.
MNKD Company Deck
MNKD Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlighted multiple near-term commercial and clinical catalysts, solid top-line growth (15% YoY) and strong operational wins (FURO6 prescriber growth, royalties up 9%, SC Pharma synergies exceeding $20M), alongside meaningful progress on pipeline programs (MNKD-201 Phase 1b and Phase 2 start) and an expanded collaboration with United Therapeutics (ralinepag DPI payment and milestone potential). Short-term challenges include seasonality, field reorganization and inventory transitions that pressured Q1 revenue and contributed to GAAP and non-GAAP losses, plus some formulation and development uncertainty for new DPI programs. Management reiterated full-year FURO6 guidance and expects acceleration in H2 tied to the ReadyFlow auto-injector and Afrezza pediatrics launch, indicating confidence that near-term investments will drive longer-term growth.View all MNKD earnings summariesMNKD Stock 12 Month Forecast
Average Price Target
$8.29
▲(102.73% Upside)
Technical Analysis
Ownership Overview
2.25% Insiders
9.74% Mutual Funds
15.21% Other Institutional Investors
57.27% Public Companies and
Individual Investors